ABBV Long Call Strategy
ABBV (AbbVie Inc.), in the Healthcare sector, (Drug Manufacturers - General industry), listed on NYSE.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation.
ABBV (AbbVie Inc.) trades in the Healthcare sector, specifically Drug Manufacturers - General, with a market capitalization of approximately $439.33B, a trailing P/E of 69.75, a beta of 0.28 versus the broader market, a 52-week range of 190.75-267.47, average daily share volume of 6.8M, a public-listing history dating back to 2013, approximately 57K full-time employees. These structural characteristics shape how ABBV stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.28 indicates ABBV has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 69.75 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple. ABBV pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a long call on ABBV?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
ABBV snapshot
As of August 14, 2026, spot at $249.52, ATM IV 22.77%, IV rank 25.89%, expected move 6.53%. The long call on ABBV below is built from the August 14, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.
Why this long call structure on ABBV specifically: ABBV IV at 22.77% is on the cheap side of its 1-year range, which favors premium-buying structures like a ABBV long call, with a market-implied 1-standard-deviation move of approximately 6.53% (roughly $16.29 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ABBV expiries trade a higher absolute premium for lower per-day decay. Position sizing on ABBV should anchor to the underlying notional of $249.52 per share and to the trader's directional view on ABBV stock.
ABBV long call setup
The ABBV long call below is built from the August 14, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ABBV at $249.52 on that close, the first option leg uses a $250.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ABBV chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ABBV shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $250.00 | $6.48 |
ABBV long call risk and reward
- Net Premium / Debit
- -$647.50
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$647.50
- Breakeven(s)
- $256.48
- Risk / Reward Ratio
- Unbounded
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
ABBV long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on ABBV. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$647.50 |
| $55.18 | -77.9% | -$647.50 |
| $110.35 | -55.8% | -$647.50 |
| $165.52 | -33.7% | -$647.50 |
| $220.69 | -11.6% | -$647.50 |
| $275.86 | +10.6% | +$1,938.07 |
| $331.02 | +32.7% | +$7,454.99 |
| $386.19 | +54.8% | +$12,971.90 |
| $441.36 | +76.9% | +$18,488.82 |
| $496.53 | +99.0% | +$24,005.73 |
When traders use long call on ABBV
Long calls on ABBV express a bullish thesis with defined risk; traders use them ahead of ABBV catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
ABBV thesis for this long call
The market-implied 1-standard-deviation range for ABBV extends from approximately $233.23 on the downside to $265.81 on the upside. A ABBV long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current ABBV IV rank near 25.89% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ABBV at 22.77%. As a Healthcare name, ABBV options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ABBV-specific events.
ABBV long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ABBV positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ABBV alongside the broader basket even when ABBV-specific fundamentals are unchanged. Long-premium structures like a long call on ABBV are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current ABBV chain quotes before placing a trade.
Frequently asked questions
- What is a long call on ABBV?
- A long call on ABBV is the long call strategy applied to ABBV (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With ABBV stock at $249.52 on the August 14, 2026 close, the strikes shown on this page are snapped to the nearest listed ABBV chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are ABBV long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the ABBV long call priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 22.77%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$647.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ABBV long call?
- The breakeven for the ABBV long call priced on this page is roughly $256.48 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The ABBV market-implied 1-standard-deviation expected move in the same options snapshot is approximately 6.53%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on ABBV?
- Long calls on ABBV express a bullish thesis with defined risk; traders use them ahead of ABBV catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current ABBV implied volatility affect this long call?
- ABBV ATM IV is at 22.77% with IV rank near 25.89%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.